Short Interest in Nuvilex Inc. (NASDAQ:PMCB) Increases By 356.3%

Nuvilex Inc. (NASDAQ:PMCB) was the recipient of a large increase in short interest during the month of May. As of May 15th, there was short interest totaling 469,898 shares, an increase of 356.3% from the April 30th total of 102,979 shares. Based on an average trading volume of 382,797 shares, the short-interest ratio is presently 1.2 days. Currently, 4.9% of the company’s shares are short sold.

Nuvilex Stock Down 2.7%

Shares of PMCB stock traded down $0.02 on Friday, hitting $0.83. The stock had a trading volume of 146,798 shares, compared to its average volume of 316,855. Nuvilex has a one year low of $0.63 and a one year high of $1.51. The business has a 50 day moving average price of $0.75 and a 200 day moving average price of $0.78. The company has a market cap of $8.96 million, a PE ratio of -0.75 and a beta of 0.46.

Analysts Set New Price Targets

A number of brokerages recently commented on PMCB. Wall Street Zen raised shares of Nuvilex to a “sell” rating in a report on Saturday, January 31st. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Nuvilex in a report on Tuesday, April 21st. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has a consensus rating of “Sell”.

About Nuvilex

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte.